Abstract
The global market for drugs treating Central Nervous System (CNS) disorders has grown rapidly in recent years to reach US$55.5 billion in 2005, a year-on-year increase of 6.6%.
Between 2003 and 2005, global CNS sales increased by 19% and accounted for 9.2% of total global pharmaceutical sales in 2005. Annual global CNS sales growth slowed from 11.5% in 2004 to 6.6% in 2005 as a result of generic competition for leading anti-depressant and epilepsy therapies.
CNS Market Trends, 2007-2010 - Key market forecasts and growth opportunities provides an in-depth analysis of the growing market for pharmaceutical treatments for central nervous system (CNS) disorders.
This comprehensive report delivers market forecasts and overviews to help inform you in your pharmaceutical business decision-making.
Particular attention is drawn to the following drug classes; Epilepsy, Alzheimer' s Disease, Migraines, ADHD, Parkinson' s Disease.
Key findings from the report include:
- The global CNS market is forecast to expand to US$63.9 billion in 2010 but growth will be limited by mature markets in depression and epilepsy and continued patent expiries for major products.
- Of the top 20 products by global CNS sales in 2005, 13 generated annual sales in excess of US$1 billion.
- 5 of the top 10 CNS companies AstraZeneca, Forest, GSK, Sanofi-Aventis and Wyeth are forecast to grow their CNS sales over the next five years. J&J, Novartis and Abbott are forecast to suffer declining CNS sales over the next five years.
- A total of 15 pharmaceutical companies were identified as having generated CNS sales in excess of US$1 billion in 2005.
- Topamax was the leading epilepsy drug in 2005 with sales of US$1.7 billion. Other blockbuster epilepsy drugs include the second generation anti-convulsant, Lamictal and traditional anti-convulsant, Depakote.
- The global market for CNS-related pharmaceuticals was dominated by the anti-depressant drug class with a market share of more than 30%
This report provides key information needed in your business including:
- Sales forecast for top ten companies providing CNS treatment medicines.
- Analysis of leading CNS products likely to loose patent protection in the next ten years.
- Sales forecasts to 2010 for the top ten CNS medicines and forecasts by drug class.
- Overview of disease incidence, areas of growth and breakdown of disease burden and mortality.
- Breakdown of the major market trends and business opportunities.
- In-depth coverage of the following companies' CNS market presence: Abbott, AstraZeneca, Eli Lilly, Forest, GlaxoSmithKline, Johnson & Johnson, Novartis, Pfizer, Sanofi-Aventis, Wyeth.
Use This Report To:
- 1. Benchmark your company' s portfolio against market trends and forecasts to plan better for greater profitability.
- 2. Spot areas of pharmaceutical market growth and good opportunities for delivering successful sales growth.
- 3. Support your internal planning processes by using an external perspective founded on detailed analysis and transparent market forecasts.
The 135 page publication contains 53 Figures and 54 Tables to help you make sense of the wealth of data. This report will be of particular use to those involved in:
- pharmaceutical company corporate planning,
- portfolio management, and,
- market and sales forecasting.
The report is divided into five key sections. Chapters 2-5 present historical trends for key disease markets, key drug classes, key products and key companies. Chapter 6 outlines future CNS market trends and major growth opportunities. The data and analysis contained within the report are comprehensive, consistent and up-to-date and thus provide a single-point of reference for understanding CNS market trends.
Table of Contents
Executive Summary
- Overview
- Key disease markets
- Key drug classes
- Key products
- Key companies
- Key trends and opportunities
Chapter 1. Overview of Global CNS Market
- Global CNS market
- Report overview
- Methodology
- Sources
Chapter 2. Key CNS Disease Markets
- Key CNS markets
- Disease burden
- CNS prevalence
- CNS mortality
- CNS epidemiology
- ADHD (Attention Deficit Hyperactivity Disorder)
- Alzheimer' s disease
- Depression
- Epilepsy
- Migraine
- Parkinson' s disease
- Schizophrenia
Chapter 3. Key CNS Drug Classes
- Key drug classifications
- Anti-depressants drug class
- Leading anti-depressant drugs
- Anti-psychotics drug class
- Leading anti-psychotics
- Epilepsy drug class
- Leading epilepsy drugs
- Alzheimer' s disease drug class
- Leading Alzheimer' s disease drugs
- Migraine drug class
- Leading migraine drugs
- ADHD drug class
- Leading ADHD drugs
- Parkinson' s disease drug class
- Leading Parkinson' s disease drugs
- Selected other drug classes
- Leading selected other CNS drugs
Chapter 4. Key CNS Products
- Leading products
- Top 10 leading CNS drugs
- Zyprexa (olanzapine)
- Risperdal (risperidone)
- Effexor (venlafaxine)
- Zoloft (sertraline)
- Seroquel (quetiapine)
- Lexapro/ Cipralex (escitalopram)
- Aricept (donepezil)
- Topamax (topiramate)
- Lamictal (lamotrigine)
- Wellbutrin (bupropion)
Chapter 5. Key Companies Involved in CNS
- Major CNS players
- Leading companies
- Johnson & Johnson
- Pfizer
- Eli Lilly
- GlaxoSmithKline
- AstraZeneca
- Wyeth
- Novartis
- Forest
- Abbott
- Sanofi-Aventis
Chapter 6. Key Trends and Opportunities in CNS
- Key disease market forecasts
- Global markets
- CNS sites
- Key drug class forecasts
- Anti-depressants
- Anti-psychotics
- Epilepsy
- Alzheimer' s disease
- Migraine
- ADHD
- Parkinson' s disease
- Selected others
- Key product forecasts
- Zyprexa (olanzapine)
- Risperdal (risperidone)
- Effexor (venlafaxine)
- Zoloft (sertraline)
- Seroquel (quetiapine)
- Lexapro/ Cipralex (escitalopram)
- Aricept (donepezil)
- Topamax (topiramate)
- Lamictal (lamotrigine)
- Wellbutrin (bupropion)
- Forecast patent expiries
- Company forecasts in the CNS area
- Johnson & Johnson
- Pfizer
- Eli Lilly
- GlaxoSmithKline
- AstraZeneca
- Wyeth
- Novartis
- Forest
- Abbott
- Sanofi-Aventis
Appendix
- Proprietary data sources
- Product Trends Database
- R&D Trends Database
- Company Trends Database
- Top 48 CNS products
- Top 15 pharmaceutical companies by CNS sales
Figures
- Figure 1: Global CNS market, 2003-2005
- Figure 2: Report structure
- Figure 3: Disease burden for CNS in seven major pharmaceutical markets, 2005
- Figure 4: Prevalence for CNS in seven major pharmaceutical markets, 2005
- Figure 5: CNS deaths in seven major pharmaceutical markets, 2005
- Figure 6: CNS epidemiology in seven major markets, 2005
- Figure 7: ADHD epidemiology in seven major markets, 2005
- Figure 8: Alzheimer' s disease epidemiology in seven major markets, 2005
- Figure 9: Depression epidemiology in seven major markets, 2005
- Figure 10: Epilepsy epidemiology in seven major markets, 2005
- Figure 11: Migraine epidemiology in seven major markets, 2005
- Figure 12: Parkinson' s disease epidemiology in seven major markets, 2005
- Figure 13: Schizophrenia epidemiology in seven major markets, 2005
- Figure 14: Global CNS market by drug class, 2005
- Figure 15: Global CNS market by drug class, 2003-2005
- Figure 16: Global CNS market trends by drug class, 2004-2005
- Figure 17: Anti-depressants drugs market, 2003-2005
- Figure 18: Leading anti-depressant drugs by approval date, 1980-2005
- Figure 19: Anti-psychotics drugs market, 2003-2005
- Figure 20: Leading anti-psychotics by approval date, 1989-2005
- Figure 21: Epilepsy drugs market, 2003-2005
- Figure 22: Leading epilepsy drugs by approval date, 1968-2005
- Figure 23: Alzheimer' s disease drugs market, 2003-2005
- Figure 24: Leading Alzheimer' s disease drugs by approval date, 1996-2005
- Figure 25: Migraine drugs market, 2003-2005
- Figure 26: Leading migraine drugs by approval date, 1992-2005
- Figure 27: ADHD drugs market, 2003-2005
- Figure 28: Leading ADHD drugs by approval date, 1996-2005
- Figure 29: Parkinson' s disease market, 2003-2005
- Figure 30: Leading Parkinson' s disease drugs by approval date, 1997-2005
- Figure 31: Selected others market, 2003-2005
- Figure 32: Leading selected other CNS drugs by approval date, 1968-2005
- Figure 33: Top 10 CNS products by global sales, 2005
- Figure 34: Top 10 companies by global CNS sales, 2005
- Figure 35: Top 10 companies by global CNS market share, 2005
- Figure 36: Top 10 companies by global CNS sales, 2004-2005
- Figure 37: CNS incidence forecasts by geographic market, 2005-2010
- Figure 38: CNS incidence forecasts by disease market, 2005-2010
- Figure 39: Global CNS market forecast, 2003-2010
- Figure 40: Global CNS market forecasts by drug class, 2003-2010
- Figure 41: Top 10 CNS drugs by forecast sales, 2010
- Figure 42: Zyprexa (olanzapine) forecast sales, 2003-2010
- Figure 43: Risperdal (risperidone) forecast sales, 2003-2010
- Figure 44: Effexor (venlafaxine) forecast sales, 2003-2010
- Figure 45: Zoloft (sertraline) forecast sales, 2003-2010
- Figure 46: Seroquel (quetiapine) forecast sales, 2003-2010
- Figure 47: Lexapro/ Cipralex (escitalopram) forecast sales, 2003-2010
- Figure 48: Aricept (donepezil) forecast sales, 2003-2010
- Figure 49: Topamax (topiramate) forecast sales, 2003-2010
- Figure 50: Lamictal (lamotrigine) forecast sales, 2003-2010
- Figure 51: Wellbutrin (bupropion) forecast sales, 2003-2010
- Figure 52: Forecast patent expiries by 2005 global sales, 2006-2015
- Figure 53: Top ten companies by CNS sales trends, 2005-2010
Tables
- Table 1: Global CNS market trends by drug class, 2003-2005
- Table 2: Leading anti-depressant drugs, 2005
- Table 3: Anti-depressants market trends, 2003-2005
- Table 4: Leading anti-psychotics, 2005
- Table 5: Anti-psychotics market trends, 2003-2005
- Table 6: Leading epilepsy drugs, 2005
- Table 7: Epilepsy drug market trends, 2003-2005
- Table 8: Leading Alzheimer' s disease drugs, 2005
- Table 9: Alzheimer' s disease drug market trends, 2003-2005
- Table 10: Leading migraine drugs, 2005
- Table 11: Migraine drugs market trends, 2003-2005
- Table 12: Leading ADHD drugs, 2005
- Table 13: ADHD drugs market trends, 2003-2005
- Table 14: Leading Parkinson' s disease drugs, 2005
- Table 15: Parkinson' s disease market trends, 2003-2005
- Table 16: Leading selected other CNS drugs, 2005
- Table 17: selected others market trends, 2003-2005
- Table 18: Top 20 CNS products by global sales, 2003-2005
- Table 19: Zyprexa (olanzapine) profile, 2005
- Table 20: Risperdal (risperidone) profile, 2005
- Table 21: Effexor (venlafaxine) profile, 2005
- Table 22: Zoloft (sertraline) profile, 2005
- Table 23: Seroquel (quetiapine) profile, 2005
- Table 24: Lexapro (escitalopram) profile, 2005
- Table 25: Aricept (donepezil) profile, 2005
- Table 26: Topamax (topiramate) profile, 2005
- Table 27: Lamictal (lamotrigine) profile, 2005
- Table 28: Wellbutrin (bupropion) profile, 2005
- Table 29: Top 10 companies by global CNS sales, 2003-2005
- Table 30: Johnson & Johnson profile, 2005
- Table 31: Johnson & Johnson pipeline, 2005
- Table 32: Pfizer profile, 2005
- Table 33: Pfizer CNS pipeline, 2005
- Table 34: Eli Lilly profile, 2005
- Table 35: Eli Lilly CNS pipeline, 2005
- Table 36: GlaxoSmithKline profile, 2005
- Table 37: GlaxoSmithKline CNS pipeline, 2005
- Table 38: AstraZeneca profile, 2005
- Table 39: AstraZeneca CNS pipeline, 2005
- Table 40: Wyeth profile, 2005
- Table 41: Wyeth CNS pipeline, 2005
- Table 42: Novartis profile, 2005
- Table 43: Novartis CNS pipeline, 2005
- Table 44: Forest profile, 2005
- Table 45: Forest CNS pipeline, 2005
- Table 46: Abbott profile, 2005
- Table 47: Abbott CNS pipeline, 2005
- Table 48: Sanofi-Aventis profile, 2005
- Table 49: Sanofi-Aventis CNS pipeline, 2005
- Table 50: Global CNS market forecasts by drug class, 2003-2010
- Table 51: Top 10 CNS drugs forecasts, 2003-2010
- Table 52: Top 10 companies by CNS sales forecasts, 2005-2010
- Table 53: Top 48 CNS products by global pharmaceutical sales, 2003-2005
- Table 54: Top 15 companies by global CNS sales, 2003-2005
